<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">32804773</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1538-943X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>67</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>ASAIO journal (American Society for Artificial Internal Organs : 1992)</Title>
          <ISOAbbreviation>ASAIO J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lean Ad hoc Extracorporeal Membrane Oxygenation Systems for COVID-19.</ArticleTitle>
        <Pagination>
          <StartPage>12</StartPage>
          <EndPage>17</EndPage>
          <MedlinePgn>12-17</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MAT.0000000000001278</ELocationID>
        <Abstract>
          <AbstractText>Coronavirus disease (COVID-19) is overwhelming hospitals with patients requiring respiratory support, including ventilators and Extracorporeal Membrane Oxygenation (ECMO). Bottlenecks in device availability may contribute to mortality, and limited device availability even in ECMO centers has led to rationing recommendations. Therefore, we explored options for ad hoc construction of venovenous ECMO using readily available components, essentially, large cannulas, membrane oxygenators, and blood pumps. As thousands of certified cardiac Impella pumps are distributed worldwide, we assembled lean ECMO by embedding Impella pumps coaxially in tubes, combined with standard gas exchangers. Ad hoc integration of Impella blood pumps with gas exchange modules, large-bore venous cannulas, regular ECMO tubing, Y-pieces, and connectors led to lean ECMO systems with stable performance over several days. Oxygenation of 2.5-5 L of blood per minute is realistic. Benefit/risk analysis appears favorable if a patient needs respiratory support but required support systems in a center are exhausted. Ad hoc assembly of venovenous ECMO is feasible using Impella blood pumps, results in stable blood flow across gas exchange modules, and thus may offer another opportunity to oxygenate, "recover the lungs" and hopefully save lives in selected patients with severe COVID-19 disease even when conventional life support equipment is exhausted. The lean design also yields inspirations for future ECMO systems.</AbstractText>
          <CopyrightInformation>Copyright © ASAIO 2020.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hunziker</LastName>
            <ForeName>Patrick</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0003-1880-5117</Identifier>
            <AffiliationInfo>
              <Affiliation>From the Intensive Care Unit, University Hospital Basel and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zenklusen</LastName>
            <ForeName>Urs</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Perfusion Unit, Cardiac Surgery, University of Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>ASAIO J</MedlineTA>
        <NlmUniqueID>9204109</NlmUniqueID>
        <ISSNLinking>1058-2916</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>S88TT14065</RegistryNumber>
          <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName>
          <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010107" MajorTopicYN="Y">Oxygenators, Membrane</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32804773</ArticleId>
        <ArticleId IdType="doi">10.1097/MAT.0000000000001278</ArticleId>
        <ArticleId IdType="pii">00002480-202101000-00005</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579:265–269</Citation>
        </Reference>
        <Reference>
          <Citation>Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8:420–422</Citation>
        </Reference>
        <Reference>
          <Citation>Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Davies A, Jones D, Bailey M, et al. Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) influenza investigators. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA. 2009; 302:1888–1895</Citation>
        </Reference>
        <Reference>
          <Citation>Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA. 2011; 306:1659–1668</Citation>
        </Reference>
        <Reference>
          <Citation>Peek GJ, Mugford M, Tiruvoipati R, et al.; CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009; 374:1351–1363</Citation>
        </Reference>
        <Reference>
          <Citation>Pham T1, Combes A, Rozé H, et al. REVA research network extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis. Am J Respir Crit Care Med. 2013; 187:276–285</Citation>
        </Reference>
        <Reference>
          <Citation>Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020; 28:1–34</Citation>
        </Reference>
        <Reference>
          <Citation>Truog RD, Mitchell C, Daley GQ. The toughest triage—allocating ventilators in a pandemic. N Eng J Med. 2020; 382:1973–1975</Citation>
        </Reference>
        <Reference>
          <Citation>Rosenbaum L. 2020. Facing Covid-19 in Italy—ethics, logistics, and therapeutics on the epidemic’s front line. N Eng J Med. 2020; 382:1873–1875</Citation>
        </Reference>
        <Reference>
          <Citation>Rubin EJ, Baden LR, Morrissey S. Audio interview: emerging tools in the fight against Covid-19. N Engl J Med. 2020; 382:e39</Citation>
        </Reference>
        <Reference>
          <Citation>Lassen HC. A preliminary report on the 1952 poliomyelitis epidemic. Lancet. 1953; 1:37</Citation>
        </Reference>
        <Reference>
          <Citation>https://edwardsprod.blob.core.windows.net/media/Default/_Profiles/8ae8ae66/f3a16810/optisite_curve-1.png?v=637073853810000000. accessed on 2020-04-06</Citation>
        </Reference>
        <Reference>
          <Citation>https://www.getinge.com/siteassets/products-a-z/hls-cannulae/hlscannulae_mcp_br_10018_en_1_screen.pdf?disclaimerAccepted=yes. accessed on 2020-04-06</Citation>
        </Reference>
        <Reference>
          <Citation>https://www.xenios-campus.com/en/topic/choosing-the-venous-drainage-cannula/. accessed on 2020-04-06</Citation>
        </Reference>
        <Reference>
          <Citation>https://www.medtronic.com/content/dam/medtronic-com/products/cardiovascular/cannulae/soft-flow-arterial-cannulae/documents/Bio-Medicus_NextGen_Brochure_1.pdf. accessed on 2020-04-06</Citation>
        </Reference>
        <Reference>
          <Citation>https://www.ema.europa.eu/en/human-regulatory/research-development/compassionate-use. accessed on 2020-04-06</Citation>
        </Reference>
        <Reference>
          <Citation>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116859/. accessed on 2020-04-06</Citation>
        </Reference>
        <Reference>
          <Citation>https://www.fda.gov/medical-devices/investigational-device-exemption-ide/expanded-access-medical-devices. accessed on 2020-04-06</Citation>
        </Reference>
        <Reference>
          <Citation>https://www.pmda.go.jp/review-services/trials/0016.html. accessed on 2020-05-08</Citation>
        </Reference>
        <Reference>
          <Citation>https://www.raps.org/news-and-articles/news-articles/2018/4/expanded-access-programs-for-medical-devices. accessed on 2020-04-06</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
